Functional collaboration between different cyclin-dependent kinase
inhibitors suppresses tumor growth with distinct tissue specificity.
Increased proteosome degradation of cyclin-dependent kinase
inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
The report includes a compilation of current active projects in research and development of synthetic molecules targeting polo-like kinase 1 (Plk-1), cyclin-dependent kinase
(CDK) or aurora kinase.
The compound has been shown in vitro to lead to the inhibition of the cell cycle, targeting all relevant cyclin-dependent kinases
, and to the induction of apoptosis (programmed cell death).
SNS-032, a selective inhibitor of cyclin-dependent kinases
2, 7 and 9, is being evaluated in Phase 1 clinical trials in B-cell malignancies and in advanced solid tumors.
Kenpaullone impedes the action of proteins called cyclin-dependent kinases
, which affect nerve cell growth and many other cell functions.
Abnormal expression of cyclin D1 and cyclin-dependent kinases
(CDKs) have been considered to be one of the most important factors in the tumourigenesis of various human malignancies.
Among the topics discussed are the QSAR computational model for identifying cyclin-dependent kinases
as a therapeutic target in lung cancer, molecular analysis of genetic risk factors for benign prostatic hyperplasia (BPH), and the relationship between obesity and cancer.
(Cdks) are proteins that are involved in the regulation of the cell cycle.
The transition through G1 to S phase is regulated by cyclins, cyclin-dependent kinases
(CDK)-CDK4 and CDK6 and their inhibitors.
Washington, May 20 (ANI): In a new clinical trial, scientists have found that SNS-032, one of the first in a new class of drugs that inhibit cyclin-dependent kinases
, is safe and could offer a potential clinical cure for advanced chronic lymphocytic leukemia (CLL).
Sample topics include centrosomes in checkpoint responses, DNA damage response and the balance between cell survival and cell death, and targeting cyclin-dependent kinases
with small molecule inhibitors.